Format

Send to

Choose Destination
See comment in PubMed Commons below
BMJ Case Rep. 2010 Oct 28;2010. pii: bcr0420102919. doi: 10.1136/bcr.04.2010.2919.

Omalizumab for severe atopic keratoconjunctivitis.

Author information

  • 1Service de pneumologie, Hôpital Bichat, Paris, France. camille.taille@bch.aphp.fr

Abstract

A 35-year-old patient received omalizumab (300 mg twice a month) for 2 years for a severe atopic keratoconjunctivitis (AKC) in order to reduce the risk for steroid-induced keratitis. After 4 months, quality of life and ocular symptoms improved, and the use of oral steroids was strongly reduced. The treatment was well tolerated. This observation suggests that omalizumab may be a good option for the treatment of severe AKC, especially to avoid side effects of immunosuppressive treatments, as suggested for other allergic diseases. Specific trials should be designed for allergic eye diseases.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk